Intensity presents positive Phase 1/2 results

Intensity Therapeutics reports positive preliminary results from the company’s ongoing Phase 1/2 clinical trial of its lead product candidate, INT230-6, in a poster at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.

“We are excited and encouraged by the positive preliminary results of our Phase 1/2 trial,” said Lewis H. Bender, President and Chief Executive Officer of Intensity Therapeutics. “It is our aim to improve cancer treatment, reduce the side effects associated with systemic therapies and improve patient outcomes using intratumorally dosed INT230-6.”